ãã€ãªãã¯ãããžãŒå ¬è¡šãããæŽå¯
æäœåžå Žã®2025幎ã®åžå ŽèŠæš¡ã¯2,85,626.6çŸäžç±³ãã«ãšæšå®ããã2032幎ã«ã¯6,67,815.1çŸäžç±³ãã«ã«éãããšäºæž¬ããã2025幎ãã2032幎ãŸã§ã®å¹Žå¹³åæé·çïŒCAGRïŒã¯12.9%ã§ããã äžçã®æäœåžå Žã«é¢ããã¢ããªã¹ãã®èŠè§£ïŒ äž»èŠåžå Žãã¬ã€ã€ãŒã«ããææºãªã©ã®ç¡æ©çæŠç¥ã®å¢å ã¯ãäºæž¬æéã«ããã£ãŠäžçã®æäœåžå ŽãçœåŒãããšäºæ³ããããäŸãã°ã2022幎3æã補è¬ã»ãã«ã¹ã±ã¢äŒæ¥ã®Sanofiãšãã€ãªãã¯ãããžãŒäŒæ¥ã®Seagen Inc.ã¯ãæå€§3ã€ã®ããæšçã«å¯Ÿããæäœè¬ç©è€åäœïŒADCïŒã®èšèšãéçºãåååã«é¢ããææºå¥çŽãçºè¡šããããã®ææºã§ã¯ããµãã... ãã£ãšèŠã
ãã©ã·ã DNA è£œé æ¥ åžå Žã¯ç±³ãã« 1,353.0 ã§è©äŸ¡ããããšæšå®ããã 2025幎ã®Mnã¯USD 5,600.8ã«éãããšäºæ³ããã 2032幎ã2025幎ãã2032幎ã«ãããŠ22.5%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºãPlasmidsã¯çްèããã³ä»ã®é¡åŸ®é¡ã®çç©ã§èŠã€ããããDNAã®å°ããåã®ååã§ãã Plasmidsã¯ãæè²äœDNAããç©ççã«åé¢ãããç¬ç«ããŠè€è£œããŸãã 圌ãã¯éåžžãå°éã®éºäŒåãæã£ãŠããŸã, ç¹ã«æçç©è³ªèæ§ã«é¢é£ä»ããããŠãããã®, 1ã€ã®çްèããå¥ã®çްèã«æž¡ãããŸã. ãã©ã·ã DNA ã¯ãéºäŒåæ²»çè¬ãã¯ã¯ãã³æåçæãªã©ã®æ²»çè¬ãšããŠçŽæ¥äœ¿... ãã£ãšèŠã
å šäœçãªãã£ãã·ã¥ã®è¡å°äœæŽ»åååšã®åžå Žã¯è©äŸ¡ããããšæšå®ãããŸã US$ 2.58 ãã³ ãåãåãã 2023幎 å±ç€ºäºå® ã«ã°ã¬ ã«ã€ã㊠5.2%(çšæ) äºå ±æéäž (2023-2030).ã¢ããªã¹ã ãã¥ãŒã¹ å šäœçãªãã£ãã·ã¥ã®è¡å°èã®æŽ»çºååšåžå Ž:çµç¹ã®ç«åп޻æ§å€ã®è¬ç©ã®åŒ·åãªãã€ãã©ã€ã³ããã³å¢å ã®ã€ãã·ã¢ããããã³æèããã°ã©ã ã«é¢é£ãã èè¡ã®ææ ãããŠmyocardialã®infarctionã¯äºæž¬æéäžã®å šäœçãªãã£ãã·ã¥ã®è¡å°ç©è³ªã®æŽ»æ§åå€ã®åžå Žæé·ãé転ãããšæåŸ ãããŸããå³1. å šäœçãªçµç¹ãã©ã¹ãããŒã²ã³ã¢ã¯ãããŒã¿ãŒ åžå Žã·ã§ã¢(%)ã ãã©ãã°ã¿ã€ã 2... ãã£ãšèŠã
幹现èè»éªšåçåžå Žã¯2025幎ã®USD 481.8 Mnã§è©äŸ¡ãããUSD 892.1ã«éãããšäºæ³ããã 2032幎ã2025幎ãã2032幎ã«ãããŠ9.2%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºãã°ããŒãã«å¹¹çްèè»éªšåçåžå Žã«é¢ããã¢ããªã¹ãã®æèŠ:ç ç©¶ã»éçºæŽ»åã®æ¡å€§ã¯ãäºæž¬æéã«ããã£ãŠäžç幹现èè»éªšåçåžå ŽãçœåŒããããšãæåŸ ãããŸãã ããšãã°ã2021幎2æã«ã¯ãåœç«ãã€ãªãã¯ãããžãŒæ å ±ã»ã³ã¿ãŒ(NCBI)ã«ããŒã¿ãå ¬éãããããã«å¿ããŠãé¢ç¯è»éªšåçããã³éªšé¢ç¯ç(OA)æ²»çã®åéã«ãããŠã幹现èãé¢äžããç ç©¶ã¯ãå®éšå®€ããã¯ãªããã¯ã«ç§»è¡ããŸããã ãããã幹现èãå«ãçµç¹å·¥... ãã£ãšèŠã
æ žé žåé¢ãšæµååžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032ã°ããŒãã«æ žé žåé¢ããã³æµååžå ŽèŠæš¡ã¯ã2025幎ãã2032幎ãŸã§ã®USD 2.15åã§è©äŸ¡ããããšæšå®ããã2032幎ãŸã§ã«USD 3.78åã«éãããšäºæ³ãããŸãããããã£ãŒã«æ žé žã®åé¢ããã³æµåãããã¯ãã¯çç©çãµã³ãã«ããDNAããã³RNAãæœåºããæµåããã®ã«äœ¿çšãããååçç©åŠã®å¿ èŠãªçšå ·ã§ãã ãããã®ã·ã¹ãã ã¯ãæåã¹ãã³åããããç£æ°ããŒãºããŒã¹ã®ã·ã¹ãã ãããã³å®å šèªåæœåºãã©ãããã©ãŒã ãå«ã¿ãŸãã PCRãã·ãŒã±ã³ã·ã³ã°ãã¯ããŒãã³ã°ãªã©ã®ããŠã³ã¹ããªãŒã ã¢ããªã±ãŒã·ã§ã³çšã®é«çŽåºŠã®éºäŒææãæäŸããããã«èšèšã... ãã£ãšèŠã
äºéç¹å®èçœè³ªã®ãããŒãŒTTKã®æå¶å€ åžå Žã¯ç±³ãã«115.2ã§è©äŸ¡ããããšæšå®ããã 2025幎ã®Mnã¯USD 471.5ã«éãããšäºæ³ããã 2032幎ã2025幎ãã2032幎ã«ãããŠ22.3%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºã ã°ããŒãã«ã»ãã¥ã¢ã«ã»ã¹ãã·ã£ãªãã£ã»ãããã€ã³ãããŒãŒTtké»å®³å€åžå Žã«é¢ããã¢ããªã¹ãã®æèŠ:äºéç¹ç°æ§ã¿ã³ãã¯è³ªãããŒãŒ Ttkã®æå¶å€ã¯ããã·ã³ã®ãããŒãŒããã³ã»ãªã³/threonineã®ãããŒãŒãšããŠæ©èœããŸãã CLK1 ãªã³ãžãªã³ãšã¢ã«ã®ãã³ãè±å¯ãªã¿ã³ãã¯è³ªãé åã Clk2 ãš Clk3 ã¯ãã»ãªã³ãšã¢ã«ã®ãã³-ãªãã(SR) ã¿ã³ãã¯è³ªã®... ãã£ãšèŠã
Microneedle Flu Vaccine åžå Žã¯ç±³ãã« 1,749.2 ã§è©äŸ¡ããããšæšå®ããã 2025幎ã®Mnã¯USD 2,682.7ã«éãããšäºæ³ããã 2032幎ã2025幎ãã2032幎ã«ãããŠ6.3%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºã ã°ããŒãã«ã»ãã€ã¯ãããŒãã«ã»ãã«ã»ã¯ã¯ãã³åžå Žã«é¢ããã¢ããªã¹ãã®æèŠ:ã€ã³ãã«ãšã³ã¶ã®æ²»çã®ããã®ãã€ã¯ãããŒãã«ãã¯ã¯ãã³ã®èª¿ééèŠã¯ãäºæž¬æéã«ããã£ãŠåžå Žæé·ãä¿é²ããããšãæåŸ ãããŠããŸãã ããšãã°ã2020幎7æã§ã¯ããªãŒãã³ãœãŒã¹ãžã£ãŒãã«ã§ãããµã€ãšã³ã¹ãã€ã¬ã¯ããçºè¡ããã¬ããŒãã«ãããšããµããŠãããæåãã¢ãžã¥ãã³ã... ãã£ãšèŠã
åäžã»ã«ã²ãã ã·ãŒã±ã³ã·ã³ã°ã¯ããã®åäžã»ã«å ã®åäžã»ã«ããã³å¢å¹ ããã³ã·ãŒã±ã³ã·ã³ã°éºäŒåãåé¢ããããšãå«ã¿ãŸãã åäžã»ã«ã®ã·ãŒã±ã³ã·ã³ã°ã¯ãåã ã®ã»ã«ããµã€ãºãã¿ã³ãã¯è³ªã¬ãã«ãããã³çºçŸRNAãã©ã³ã¹ã¯ãªããã®å€§ããªç¯å²ã§ç°ãªãå ŽåããããŸãã®ã§ãéèŠãªéèŠåºŠãéã³ãŸãã ãããã®ããªãšãŒã·ã§ã³ã¯ãããç ç©¶ã幹现èçç©åŠãå ç«åŠãçºéçç©åŠãç¥çµåŠãªã©ã®ããã€ãã®ç ç©¶ã¢ããªã±ãŒã·ã§ã³ã«é¢ããéèŠãªæŽå¯ãæäŸã§ããŸãã åäžã»ã«è§£æã«ãããåã ã®çްèã®éºäŒåçºçŸãè¿èŠããè€éãªçµç¹ã®æ©èœãçè§£ããŸãããªã©ã®æè¡ãã©ãããã©ãŒã ã«åºã¥ãããããæ©åš æ¬¡äžä»£ã·ãŒã±ã³ã·ã³ã°(NGS)ãããªã¡... ãã£ãšèŠã
æ€ç©ããŒã¹ã®ã¯ã¯ãã³ åžå Žã¯USD 219.7ã§è©äŸ¡ããããšæšå®ããã 2025幎ã®Mnã¯USD 3,987.5ã«éãããšäºæ³ãããŸã 2032幎ã®Mnã¯ã2025幎ãã2032幎ã«ãããŠ51.3%ã®ååç©ã®å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸããã°ããŒãã«æ€ç©ããŒã¹ã®ã¯ã¯ãã³åžå Žã«é¢ããã¢ããªã¹ãã®æèŠ:æ€ç©æ§ã¯ã¯ãã³ã®ç ç©¶éçºã¯ãäºæž¬æéã«ããã£ãŠåžå Žã®æé·ãä¿é²ããããšãæåŸ ãããŸãã äŸãã°ã2021幎9æãã«ãªãã©ã«ãã¢ã»ãªããŒãµã€ãã®ãžã§ããã£ãã¯ã»ãšã³ãžãã¢ãªã³ã°&ãã€ãªãã¯ãããžãŒã»ãã¥ãŒã¹ã»ãŠãããŒã¹ãçºè¡šããããŒã¿ã«ãããšãç ç©¶è ã¯ãmRNAã¯ã¯ãã³å·¥å Žã«ã¬ã¿ã¹ãã€ããããš... ãã£ãšèŠã
ãšããžã§ããã£ã¯ã¹åžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032ã°ããŒãã«ãšããžã§ããã£ã¯ã¹ åžå ŽèŠæš¡ã¯ã2025幎ã«USD 3.42åã§è©äŸ¡ããããšæšå®ããã2032幎ãŸã§ã®14.8%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããUSD 8.79åç±³ãã«ã«éãããšäºæ³ãããããããã£ãŒã«ãšããžã§ããã£ãã¯ã¹è£œåã¯ãDNAã·ãŒã±ã³ã¹ã倿ŽããããšãªããéºäŒåçºçŸã®éºäŒçå€åãç ç©¶ããããã«èšèšãããå¹ åºãç ç©¶ããŒã«ã詊è¬ãããã³åæãã©ãããã©ãŒã ãç¶²çŸ ããŠããŸãã äž»ãªè£œåã«ããŽãªã«ã¯ãDNAã¡ãã«åãããããã¹ãã³ä¿®æ£ã¢ãã»ã€ãã¯ãããã³å ç«æž¬å®(ChIP)詊è¬ã 次äžä»£ã·ãŒã±ã³ã·ã³ã°(NGS))ã·... ãã£ãšèŠã
Remicadeãã€ãªã·ãã©ãŒ åžå ŽèŠæš¡ãšäºæž¬ â 2025 â 2032ã°ããŒãã«ãªãã±ãŒããã€ãªã·ãã©ãŒ åžå ŽèŠæš¡ã¯ã2025幎ã«1åç±³ãã«3.8åç±³ãã«ã§è©äŸ¡ããã2032幎ãŸã§ã«1åç±³ãã«9åç±³ãã«ã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®1.5%ã®ååç©ã®å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«ã«ãªãã¥ã©ã ãã€ãªã·ãã©ãŒ ã¢ãã¯ããŒãã«æäœããŒã¹ã®ãã€ãªããžã«ã«è£œåã¯ãããšããšãã©ã³ãåRemicadeã®äžã§è²©å£²ãããŠããTNF-αé»å®³å€ã§ããinfliximabã坿¥ã«åçŸããããã«èšèšããããã®ã§ãã ãããã®ãã€ãªã·ãã©ãŒã¯ããªã¥ãŒãããé¢ç¯çãã¯ããŒã³ç ... ãã£ãšèŠã
å°å ã¯ã¯ãã³ åžå Žã¯ç±³ãã«52,093.1ã§è©äŸ¡ããããšæšå®ããã 2025幎ã®Mnã¯USD 77,967.4ã«éãããšäºæ³ããã 2032幎ã®Mnã¯2025幎ãã2032幎ã«ãããŠ5.93%ã®æ··åç©ã®å¹Žéæé·ç(CAGR)ãå±ç€ºããŸããã°ããŒãã«å°å ã¯ã¯ãã³åžå Žã«é¢ããã¢ããªã¹ãã®æèŠ:2021幎10æ6æ¥ äžçä¿å¥æ©é¢(WHO) ãµããµãã©ã³ã¢ããªã«ãä»ã®å°åã§ã®å°å ã¯ãé©åºŠã«é«ãP.ãã¡ã«ã·ã ãã©ãªã¢äŒéã«é©å¿ããŠããããšãçºè¡šãããŸãããRTSãS/AS01(RTSãS)ãã©ãªã¢ã¯ã¯ãã³ã宿çã«åãåãããšããå§ãããŸãã ãã®ã¢ããã€ã¹ã¯ãã¬ãŒããã±ãã€ããã©ãŠã€ã§å®è¡ãããŠãã詊... ãã£ãšèŠã
ããããã£åžå Žã¯2025幎ã«568.3çŸäžç±³ãã«ãšæšå®ããã2032幎ã«ã¯2,576.2çŸäžç±³ãã«ã«éãããšäºæž¬ããã2025幎ãã2032幎ãŸã§ã®å¹Žå¹³åæé·çïŒCAGRïŒã¯24.1ïŒ ã瀺ãã äžçã®ããããã£åžå Žã«é¢ããã¢ããªã¹ãã®èŠè§£ïŒããããã£ã¯ãããã¹ã±ãŒã«ã®å€§ããã匷åºãªæ§é ãæ°Žæº¶æ¶²äžã§ã®å®å®ãã坿º¶æ§ã®æåãå¯éçãªãªãã©ãŒã«ãã£ã³ã°ã1ã€ã®æšçã®ã¿ã«å¯Ÿããé«ãèŠªåæ§ãšç¹ç°æ§ãªã©ã®ãŠããŒã¯ãªç¹æ§ãæã€ã©ãééã®ã¿ã®æäœããæŽŸçããåäžãã¡ã€ã³ã®æäœã§ãããCOVID-19ã®ãããªãŠã€ã«ã¹ææçã®èšºæã«ãããããæäœã®å¿çšã®å¢å ã¯ãäºæž¬æéã«ããã£ãŠäžçã®ããæäœåžå Žã®æé·ãä¿é²ãã... ãã£ãšèŠã
ããããããŒããŠã€ã«ã¹ææçã¯ã¯ãã³åžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032ã°ããŒãã«ã»ãã¥ãŒãã³ã»ããããŒããŠã€ã«ã¹ ææã¯ã¯ãã³åžå ŽèŠæš¡ã¯ã2025幎ã®USD 6.8åã§è©äŸ¡ããããšæšå®ããã2032幎ãŸã§ã®USD 13.4åãã«ã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®10.2%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããŠããŸãããããã£ãŒã«HPVã«ã€ã㊠ã¯ã¯ãã³ é«ãªã¹ã¯HPVã®ç·åŒµããææãé²ãããã«èšèšãããå ç«åŠç補åã§ãåå®®é žéšã錻ãããã³ä»ã®çã«ã€ãªããããšãã§ããŸãã ãããã®ã¯ã¯ãã³ã¯ãäžè¬çã«çµã¿æãããŠã€ã«ã¹ã®ãããªç²å(VLP)ããŒã¹ã®åŠæ¹ã§ãããã©ã€ããŠã€... ãã£ãšèŠã
éºäŒååæåžå ŽèŠæš¡ãšäºæž¬ - 2025 - 2032ã°ããŒãã«ãžã§ãã·ã¹ åžå ŽèŠæš¡ã¯ã2025幎ã«2åç±³ãã«ã§è©äŸ¡ããã2032幎ãŸã§ã«1åç±³ãã«ã«1åç±³ãã«ã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®12.5%ã®ååç©ã®å¹Žéæé·ç(CAGR)ã瀺ãããããã£ãŒã«éºäŒååæè£œåã¯ãèªååããããªãªãŽãã¯ã¬ãªããã¢ã»ã³ããªãšã¯ããŒãã³ã°æè¡ã䜿çšããŠäœãããã«ã¹ã¿ã èšèšãããDNAã·ãŒã±ã³ã¹ãå«ã¿ãŸãã ãããã®åæéºäŒåã¯ãæ§ã ãªãã¹ãã·ã¹ãã ã§è¡šçŸããããã«æé©åãããç ç©¶ããã€ãªå»è¬å補é ãåæçç©åŠã«äœ¿çšãããŸãã çŸä»£ã®éºäŒååæããããšãµãŒãã¹ã¯ãè¿ éãªã¿ãŒã³ã¢ã©ãŠã³ãæéããš... ãã£ãšèŠã
ãã€ãªããŒã«ãŒåžå Žã¯ã2025幎ã«ã¯815åç±³ãã«ãšæšå®ããã2032幎ã«ã¯1,989å8,000äžç±³ãã«ã«éãããšäºæž¬ããã2025幎ãã2032幎ãŸã§ã®å¹Žå¹³åæé·çïŒCAGRïŒã¯13.6%ã§ããããã€ãªããŒã«ãŒã¯ã身äœã®ããã»ã¹ãæ£åžžãç°åžžãã瀺ããããç æ°ã®èšºæã«äœ¿çšãããååã§ããããã€ãªããŒã«ãŒã«ã¯ãããªãã·ãªãæ žé žïŒDNAïŒãã¿ã³ãã¯è³ªããã«ã¢ã³ãªã©ãå¥åº·ç¶æ ã«é¢ããæ å ±ãæäŸããããããååãå«ãŸãããç»åãã€ãªããŒã«ãŒãååãã€ãªããŒã«ãŒãªã©ãæ§ã ãªèŠå ã«åºã¥ããŠåé¡ãããããã€ãªããŒã«ãŒã掻çšããããšã§ãå»è¬åéçºã®æåçãé«ããã³ã¹ããåæžããæ£è ã®è»¢åž°ãæ¹åããããšãã§ã... ãã£ãšèŠã
ãšãã©ã¯ã¯ãã³ åžå ŽèŠæš¡ãšäºæž¬ â 2025 â 2032ã°ããŒãã«ãšãã©ã¯ã¯ãã³ åžå ŽèŠæš¡ã¯ã2025幎ã«1.2åç±³ãã«ã§è©äŸ¡ããã2032幎ãŸã§ã®14.8%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€ºããUSD 3.4åç±³ãã«ã«éãããšäºæ³ãããããããã£ãŒã«Ebolaã¯ã¯ãã³ã¯ãEbolaãŠã€ã«ã¹ã«å¯Ÿããå ç«ãèªçºããããã«éçºãããçç©åŠç補åã§ãã çæ ž ç±ã ãããã®ã¯ã¯ãã³ã¯ãç¡å®³ãªãŠã€ã«ã¹ããšãã©è¡šé¢ç³ã¿ã³ãã¯è³ªãéºäŒåãšã³ã³ãŒãã£ã³ã°ããå ç«åå¿ãåºæ¿ããéºäŒåãæäŸããŸãã rVSV-ZEBOVã®ãããªçŸåšã®ã¯ã¯ãã³ã¯ãçèå ã§æäžããããŠã€ã«ã¹ã®Zaireã®ç·åŒµã«å¯Ÿãã匷åãªä¿è·... ãã£ãšèŠã
Hematopoieticã®å¹¹çްèã®ç§»æ€(HSCT)ã®åžå Žã¯2025幎ã«USD 3.56 Bnã§è©äŸ¡ããã2032幎ã«USD 7.48 Bnã«éãããšäºæ³ããã2025幎ãã2032幎ãŸã§ã®æ··åç©ã®å¹Žéæé·ç(CAGR)ãå±ç€ºããŸãã ã°ããŒãã« Hematopoietic Stem Cell Transplantation (HSCT) ã«é¢ããã¢ããªã¹ãã®æèŠ åžå Ž:äž»èŠãªåžå Žãã¬ã€ã€ãŒã«ããæè³ãšè³é調éã¯ãäºæž¬æéã«ããã£ãŠåžå Žæé·ãä¿é²ããããšãæåŸ ãããŸãã ããšãã°ã2021幎11æã«ã¯ãã¹ã±ãŒã©ãã«ããªãã»ã¶ã»ã·ã§ã«ããæ¬¡äžä»£å¹¹çްèããŒã¹ã®å»è¬åãçºèŠããæäŸããããšã«çŠç¹ãåœ... ãã£ãšèŠã